YOLFTbeta
Assembly Biosciences Inc

Assembly Biosciences Inc

ASMB · NASDAQ · Healthcare / Biotechnology

21.12USD+0.94 (+4.66%)

Price History

Full chart

Market Stats

Previous Close20.18
Open19.96
Day Range19.22 – 21.21
52-Week Range21.80 – 39.71
Volume318.90K
Market Cap481.73M
P/E (TTM)19.08
Forward P/E500.00
EPS1.24
Dividend Yield0.00%
Beta1.13
50-Day Avg29.24
200-Day Avg28.79

About

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jason A. Okazaki J.D.
  • Employees73
  • HeadquartersTwo Tower Place, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.assemblybio.com

Leadership

  • Mr. Jason A. Okazaki J.D.CEO, President & Director · b. 1976
  • Dr. William E. Delaney IV, Ph.D.Chief Scientific Officer · b. 1972
  • Dr. Anuj Gaggar M.D., Ph.D.Chief Medical Officer · b. 1978
  • Ms. Jeanette M. BjorkquistPrincipal Financial Officer, Executive Director of Accounting & Treasury · b. 1987
  • Mr. Shannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance Management
  • Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHRChief Human Resources Officer
  • Dr. Nicole S. White Ph.D.Chief Manufacturing Officer · b. 1980
  • Ms. Katie KitrinosSenior VP of Preclinical Research & Development
  • Mr. Thomas E. RollinsExecutive Officer · b. 1956
  • Amy Figueroa C.F.A.Investor Relations Consultant

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---0000009.02M14.80M15.96M79.11M6.25M07.16M28.52M72.30M
Growth (%)----------+64.15%+7.83%+395.55%-92.09%-100.00%-+298.16%+153.52%
Cost of Revenue---00023.96M64.99K80.25K44.23M72.74M85.76M101.34M466.00K498.00K48.90M55.93M129.00K
Gross Profit---000-23.96M-64.99K-80.25K-35.21M-57.94M15.96M-22.23M6.25M-498.00K-41.74M-27.41M72.17M
Gross Margin----------390.37%-391.36%100.00%-28.10%100.00%--582.67%-96.12%99.82%
Operating Expense---34.00M24.86M19.60M029.59M45.20M17.02M34.80M118.68M42.54M138.94M93.62M22.91M18.01M84.29M
Operating Income-7.16M-3.34M-4.77M-34.00M-24.86M-19.60M-23.96M-29.66M-45.28M-52.23M-92.73M-102.71M-64.78M-132.69M-94.11M-64.65M-45.42M-12.12M
Operating Margin----------579.09%-626.42%-643.44%-81.89%-2121.65%--902.50%-159.26%-16.76%
EBITDA-7.16M-3.33M-13.23M-46.72M-24.79M-19.40M-23.95M-29.59M-44.80M-52.01M-92.73M-102.22M-58.40M-90.58M-93.62M-60.74M-39.72M-5.99M
EBITDA Margin----------576.67%-626.42%-640.35%-73.83%-1448.42%--848.04%-139.26%-8.29%
Net Income-8.79M-4.54M-15.29M-34.34M-24.79M-19.40M-23.79M-28.45M-44.26M-42.81M-90.75M-97.63M-62.15M-129.85M-92.07M-61.23M-40.18M-6.12M
Net Income Margin----------474.66%-613.02%-611.63%-78.57%-2076.35%--854.78%-140.87%-8.47%
R&D5.98M2.94M1.85M25.28M19.51M15.03M10.72M18.36M33.09M44.23M72.74M85.76M106.82M68.52M69.98M48.90M55.93M64.81M
R&D as % of Total Revenue---------490.37%491.36%537.22%135.04%1095.68%-682.67%196.12%89.64%
Interest Expense1.64M1.20M10.53M116.66K00000004.80M2.62M82.51M498.00K---
Interest Expense % of Total Revenue---------0.00%0.00%30.06%3.32%1319.28%----

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets870.39K166.25K14.62M37.05M20.56M27.13M71.23M133.74M98.12M169.30M268.05M347.89M283.25M191.06M101.79M136.82M119.17M257.59M
Total Liabilities10.33M13.53M2.99M2.51M2.75M2.64M12.65M15.00M18.24M56.18M57.39M74.67M42.68M22.13M19.13M95.73M85.81M50.84M
Total Equity-9.46M-13.36M11.63M34.53M17.81M24.49M58.57M118.74M79.88M113.12M210.65M273.22M240.58M168.93M82.66M41.10M33.36M206.75M
Cash15.85K81.29K14.57M36.98M20.49M27.06M29.09M27.11M28.58M82.03M41.47M46.73M59.44M45.63M52.42M19.84M38.34M58.45M
Total Debt5.79M9.01M2.49M--------12.27M10.13M6.48M3.46M2.34M3.09M2.63M
Net Debt5.77M8.93M-12.08M-36.98M-20.49M-27.06M-29.09M-27.11M-28.58M-82.03M-41.47M-34.46M-49.31M-39.15M-48.95M-17.50M-35.26M-55.82M

Cash Flow

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.15M-3.48M-5.21M-25.07M-21.38M-17.80M-14.97M-18.70M-34.88M1.86M-64.96M-84.07M-62.96M-93.40M-84.46M22.74M-51.12M-41.09M
Investing Cash Flow-2.88K-2.57K--11.96K-3.24K-6.48K277.40K-64.86M36.20M-15.64M-135.40M-50.32M68.07M26.52M90.64M-69.14M40.17M-113.47M
Financing Cash Flow2.50M3.55M19.70M47.49M4.90M24.37M16.73M81.57M152.64K67.24M159.79M139.65M7.60M53.06M614.00K13.82M29.45M174.67M
Capital Expenditure2.88K2.57K011.96K3.24K6.48K149.96K58.26K146.33K864.56K340.00K1.55M2.22M3.10M102.00K255.00K28.00K66.00K
Free Cash Flow-4.15M-3.49M-5.21M-25.08M-21.38M-17.80M-15.12M-18.76M-35.03M995.52K-65.30M-85.62M-65.18M-96.49M-84.56M22.49M-51.15M-41.16M
Dividends Paid---0000000--------
FCF to OCF100.07%100.07%100.00%100.05%100.02%100.04%101.00%100.31%100.42%53.52%100.52%101.85%103.53%103.31%100.12%98.88%100.05%100.16%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateMar 2, 2011May 16, 2011Aug 15, 2011Nov 14, 2011Mar 14, 2012May 9, 2012Aug 9, 2012Nov 13, 2012Mar 18, 2013May 10, 2013Aug 9, 2013Nov 12, 2013Mar 17, 2014May 14, 2014Aug 14, 2014Nov 17, 2014Mar 12, 2015May 8, 2015Aug 13, 2015Nov 9, 2015Mar 11, 2016May 11, 2016Aug 9, 2016Nov 9, 2016Mar 2, 2017May 8, 2017Aug 9, 2017Nov 1, 2017Mar 8, 2018May 7, 2018Aug 8, 2018Nov 8, 2018Feb 28, 2019May 9, 2019Aug 5, 2019Nov 7, 2019Mar 4, 2020May 8, 2020Aug 5, 2020Nov 5, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 10, 2022May 12, 2022Aug 9, 2022Nov 8, 2022Mar 22, 2023May 4, 2023Aug 9, 2023Nov 8, 2023Jan 31, 2024May 8, 2024Aug 8, 2024Nov 7, 2024Mar 26, 2025May 8, 2025Aug 6, 2025Nov 10, 2025Dec 31, 2025May 7, 2026Aug 13, 2026Nov 9, 2026
EPS Estimate--21.60-28.80-30.00-5.42-31.56-34.71-20.60-1.54-13.20-12.75-15.60-1.40-8.40-9.00-5.82-7.44-------8.04-8.04-0.03-9.48-10.56-0.79-9.84-10.86-11.82-0.90-12.24-13.68-11.00-1.01-11.043.54-9.12-0.90-9.60-8.25-7.14-0.48-4.88-5.76-6.48-0.45-4.68-3.18-2.76-2.88-3.23-2.23-1.85-1.75-1.60-1.73-0.65-0.85-0.64-0.70-0.44
EPS Actual-1416.00-22.80-58.20-30.00-8.90-39.60-35.40-24.60-1.40-13.20-14.40-15.00-0.29-10.80-6.24-15.96-7.80-0.64-0.41-0.38-0.45-0.64-0.59-8.04-8.04-0.81-9.36-8.52-0.36-9.60-15.60-10.44-1.03-12.60-8.64-11.52-0.99-9.122.28-1.08-0.96-8.28-6.60-4.92-0.38-5.76-6.12-5.76-0.46-4.44-3.84-3.24-2.15-1.66-1.98-1.51-1.57-1.17-1.33-0.722.48-0.54-0.20-
Surprise--5.56%-102.08%0.00%-64.21%-25.48%-1.99%-19.42%9.09%0.00%-12.94%3.85%79.29%-28.57%30.67%-174.23%-4.84%------0.00%0.00%-2600.00%1.27%19.32%54.43%2.44%-43.65%11.68%-14.44%-2.94%36.84%-4.73%1.98%17.39%-35.59%88.16%-6.67%13.75%20.00%31.09%20.83%-18.03%-6.25%11.11%-2.22%5.13%-20.75%-17.39%25.35%48.61%11.21%18.38%10.29%26.88%23.12%-10.77%392.90%15.63%71.43%-
Timing-After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-market-After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap481.73M
Enterprise Value200.17M
Trailing P/E19.08
Forward P/E500.00
PEG Ratio0.00
Price / Sales6.44
Price / Book1.70
EPS1.24
Book Value15.40
Revenue (TTM)74.84M
Gross Profit (TTM)11.19M
EBITDA-8.69M
Profit Margin-0.06%
Operating Margin-47.44%
Return on Equity-0.03%
Return on Assets-2.67%
Shares Outstanding20.36M
Shares Float9.17M
Beta1.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 52.00
  • Strong Buy
    2

Ownership Breakdown

Institutions
69.50%
Insiders
27.66%
Retail / Other
2.84%

Top Institutional Holders

  • Paradigm Biocapital Advisors LP
    1.55M7.83%
  • Farallon Capital Management, L.L.C.
    1.23M6.18%
  • RA Capital Management, LLC
    1.02M5.14%
  • COMMODORE CAPITAL LP
    1.00M5.04%
  • HHG PLC
    849.31K4.28%
  • Parkman Healthcare Partners LLC
    721.18K3.63%
  • Vanguard Capital Management, LLC
    490.45K2.47%
  • StemPoint Capital LP
    370.87K1.87%
  • Point72 Asset Management, L.P.
    344.11K1.73%
  • Millennium Management LLC
    298.81K1.51%
  • Blackstone Inc
    296.86K1.50%
  • Aberdeen Group PLC
    207.05K1.04%
  • BlackRock Inc
    202.74K1.02%
  • Affinity Asset Advisors, LLC
    190.00K0.96%
  • B Group, Inc
    175.71K0.89%
  • Marshall Wace Asset Management Ltd
    163.40K0.82%
  • Squadron Capital Management LLC
    160.00K0.81%
  • Ally Bridge Group (NY) LLC
    140.00K0.71%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    413.28K2.08%
  • iShares Russell 2000 ETF
    241.34K1.22%

Stock Splits

  • Feb 12, 20241:12
  • Jul 14, 20141:5